TSE:MDNA Medicenna Therapeutics (MDNA) Stock Price, News & Analysis C$0.54 -0.12 (-18.18%) As of 09:45 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Medicenna Therapeutics Stock (TSE:MDNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Medicenna Therapeutics alerts:Sign Up Key Stats Today's RangeC$0.51▼C$0.6250-Day RangeC$0.57▼C$0.8952-Week RangeC$0.51▼C$1.97Volume193,189 shsAverage Volume107,333 shsMarket CapitalizationC$45.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients. Read More Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDNA Stock News HeadlinesMedicenna Announces the Launch of a Marketed Public Offering of SecuritiesMay 13 at 4:01 PM | globenewswire.comMedicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant MelanomaMay 12 at 7:00 AM | globenewswire.comThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requires more electricity than some small countries use in a year, and SEC rules require it be disclosed. When that figure goes public, every analyst on Wall Street will race to identify the supplier. One small company already has a $1.5 billion backlog - and Dylan Jovine has the name and ticker.May 14 at 1:00 AM | Behind the Markets (Ad)Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026April 30, 2026 | globenewswire.comMedicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026April 21, 2026 | finance.yahoo.comStocks in play: Medicenna Therapeutics Corp.April 14, 2026 | ca.finance.yahoo.comMedicenna Taps Pembrolizumab Veteran as CMO to Steer Superkine Immunotherapy PipelineApril 9, 2026 | tipranks.comMedicenna Refreshes Board With Capital Markets and Biotech Leadership ExpertiseFebruary 13, 2026 | tipranks.comSee More Headlines MDNA Stock Analysis - Frequently Asked Questions How have MDNA shares performed this year? Medicenna Therapeutics' stock was trading at C$0.92 at the beginning of 2026. Since then, MDNA stock has decreased by 28.3% and is now trading at C$0.66. How were Medicenna Therapeutics' earnings last quarter? Medicenna Therapeutics Corp. (TSE:MDNA) announced its quarterly earnings data on Thursday, April, 30th. The company reported ($0.06) earnings per share for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative trailing twelve-month return on equity of 103.51%. How do I buy shares of Medicenna Therapeutics? Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Medicenna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medicenna Therapeutics investors own include Manulife Financial (MFC), Gilead Sciences (GILD), OPKO Health (OPK), Air Canada (AC), Athersys (ATHX), Birchcliff Energy (BIR) and Canadian Natural Resources (CNQ). Company Calendar Last Earnings4/30/2026Today5/14/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolTSE:MDNA CIKN/A Webwww.medicenna.com Phone+1-403-6807898FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$25.98 million Net Margins-533,640.00% Pretax MarginN/A Return on Equity-103.51% Return on Assets-32.80% Debt Debt-to-Equity Ratio3.30 Current Ratio2.68 Quick Ratio4.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.58 per share Price / Cash Flow1.15 Book ValueC$0.07 per share Price / Book8.86Miscellaneous Outstanding Shares83,420,000Free FloatN/AMarket CapC$55.06 million OptionableNot Optionable Beta2.90 The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (TSE:MDNA) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersThe US sanctioned itself out of world reserve status…Russia and Iran are both bypassing the US petrodollar - settling oil trades in alternative currencies while ce...Golden Portfolio | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredSecret behind near perfectly timed stock trades…?After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...Traders Agency | SponsoredIs this AI lab Elon’s SpaceX lifeline?Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...Chaikin Analytics | SponsoredMillionaire warns: Move your money before May 15Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2...Brownstone Research | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicenna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.